FDA approves Brukinsa tablet for CLL, certain B-cell lymphomas
The U.S. Food and Drug Administration (FDA) has approved a tablet formulation of Beone Medicines’ Brukinsa (zanubrutinib) — previously marketed by the developer in…
The U.S. Food and Drug Administration (FDA) has approved a tablet formulation of Beone Medicines’ Brukinsa (zanubrutinib) — previously marketed by the developer in…
Nearly 1 in 4 people with NPM1-mutated acute myeloid leukemia (AML) achieved complete remission after treatment with ziftomenib in a Phase 2 clinical trial. Dubbed…
A team led by a Rice University researcher received a grant to investigate treatments targeting mitochondria for acute amyloid leukemia (AML), a type of…
The first participant in a U.S. Phase 1 clinical trial testing T-cell therapy candidate CER-1236 — Cero Therapeutics’ treatment for people with acute myeloid…
ELVN-001, an experimental treatment for chronic myeloid leukemia (CML), a type of blood cancer, is showing promising proof-of-concept effects for killing cancer cells in patients…
A European regulatory committee has recommended approval of a fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) for adults with previously untreated chronic lymphocytic leukemia…
Simultaneously blocking the activity of two proteins, LSD1 and GSK3, may be an effective strategy to treat acute myeloid leukemia (AML), an aggressive type of…
April 21 marks AML World Awareness Day — a global effort to boost recognition of acute myeloid leukemia (AML) and raise funds for research…
The first patient has been dosed in a Phase 1 clinical trial evaluating the safety and early efficacy of STX-0712 in people with resistant or…
Exportin-1, a therapeutic target for nuclear export inhibitors — a class of drugs used to treat blood cancers including multiple myeloma and leukemia…